Peter Thomas

Peter Thomas

Auto-generated profile, based on publicly available information

Peter Thomas

Bournemouth University

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2004 in BMJ
Verified
Journal Article
Open access
PDF file
JJJanet James
Janet James
PTPeter Thomas
Peter Thomas
DCDavid Cavan
David Cavan
DKDavid Kerr
David Kerr
Objective To determine if a school based educational programme aimed at reducing consumption of carbonated drinks can prevent excessive weight gain in children. Design Cluster randomised controlled trial. Setting Six primary schools in southwest England. Participants 644 children aged 7-11 years. Intervention Focused educational programme on nutrition over one school year. Main outcome measures Drink consumption and number of overweight and obese children. Results Consumption of carbonated drinks over three days decreased by 0.6 glasses (average glass size 250 ml) in the intervention group but increased by 0.2 glasses in the control group (mean difference 0.7, 95% confidence interval 0.1 to 1.3). At 12 months the percentage of overweight and obese children increased in the control group by 7.5%, compared with a decrease in the intervention group of 0.2% (mean difference 7.7%, 2.2% to 13.1%). Conclusion A targeted, school based education programme produced a modest reduction in the number of carbonated drinks consumed, which was associated with a reduction in the number of overweight and obese children.

1 February 2002 in Blood
Verified
Journal Article
Open access
THTerry J. Hamblin
Terry J. Hamblin
JOJenny A. Orchard
Jenny A. Orchard
RIRachel E. Ibbotson
Rachel E. Ibbotson
ZDZadie Davis
Zadie Davis
PTPeter W. Thomas
Peter W. Thomas
DODavid G. Oscier
David G. Oscier
Although the presence or absence of somatic mutations in the immunoglobulin variable region (IgVH) genes in chronic lymphocytic leukemia (B-CLL) identifies subtypes with very different prognoses, the assay is technically complex and unavailable to most laboratories. CD38 expression has been suggested as a surrogate marker for the 2 subtypes. IgVHmutations and CD38 expression in 145 patients with B-CLL with a long follow-up were compared. The 2 assays gave discordant results in 41 patients (28.3%). Multivariate analysis demonstrated that Binet stage,IgVH mutations and CD38 were independent prognostic indicators. Median survival time in patients whose cells had unmutated IgVH genes and expressed CD38 was 8 years; in those with mutated IgVHgenes not expressing CD38, it was 26 years. For those with discordant results, median survival time was 15 years. Thus, although CD38 expression does not identify the same 2 subsets as IgVHmutations in CLL, it is an independent risk factor that can be used with IgVH mutations and clinical stage to select patients with B-CLL with the worst prognoses. Using cryopreserved cells taken at intervals during the course of the disease, however, changes of CD38 expression over time were demonstrated in 10 of 41 patients. Causes of the variation of CD38 expression require further study. Additional prospective studies are required for comparing CD38 expression with other prognostic factors and for taking sequential measurements during the course of the disease.

1 January 2004 in The Lancet
Verified
Journal Article
Closed access
JOJenny A Orchard
Jenny A Orchard
RIRachel E Ibbotson
Rachel E Ibbotson
ZDZadie Davis
Zadie Davis
AWAdrian Wiestner
Adrian Wiestner
ARAndreas Rosenwald
Andreas Rosenwald
DODavid G Oscier
David G Oscier

15 August 2002 in Blood
Verified
Journal Article
Open access
PDF file
DODavid G. Oscier
David G. Oscier
AGAnne C. Gardiner
Anne C. Gardiner
SMSarah J. Mould
Sarah J. Mould
SGSharron Glide
Sharron Glide
ZDZadie A. Davis
Zadie A. Davis
THTerry J. Hamblin
Terry J. Hamblin
This study evaluates the prognostic significance of genetic abnormalities (detected at or shortly after presentation), clinical stage, lymphocyte morphology, CD38 expression, and IGVHgene status in 205 patients with chronic lymphocytic leukemia (B-CLL). Deletion of chromosome 11q23, absence of a deletion of chromosome 13q14, atypical lymphocyte morphology, and more than 30% CD38 expression are significantly associated with the presence of unmutatedIGVH genes. Advanced stage, male sex, atypical morphology, more than 30% CD38 expression, trisomy 12, deletion of chromosome 11q23, loss or mutation of the p53 gene, and unmutatedIGVH genes are all poor prognostic factors in a univariate analysis. However, only 98% or more homology of IGVH genes to the germline sequence, loss or mutation of the p53 gene, and clinical stage retain prognostic significance in a multivariate analysis. The median survival of patients with mutated IGVHgenes, unmutated IGVH genes, and loss or mutation of thep53 gene regardless of IGVH gene status is 310, 119, and 47 months, respectively. These data should facilitate the design of new trials for the management of patients presenting with advanced disease or poor prognosis early stage disease.

20 April 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CHCaroline J. Hoffman
Caroline J. Hoffman
SESteven J. Ersser
Steven J. Ersser
JHJane B. Hopkinson
Jane B. Hopkinson
PNPeter G. Nicholls
Peter G. Nicholls
JHJulia E. Harrington
Julia E. Harrington
PTPeter W. Thomas
Peter W. Thomas
Purpose To assess the effectiveness of mindfulness-based stress reduction (MBSR) for mood, breast- and endocrine-specific quality of life, and well-being after hospital treatment in women with stage 0 to III breast cancer. Patients and Methods A randomized, wait-listed, controlled trial was carried out in 229 women after surgery, chemotherapy, and radiotherapy for breast cancer. Patients were randomly assigned to the 8-week MBSR program or standard care. Profile of Mood States (POMS; primary outcome), Functional Assessment of Cancer Therapy–Breast (FACT-B), Functional Assessment of Cancer Therapy–Endocrine Symptoms (FACT-ES) scales and the WHO five-item well-being questionnaire (WHO-5) evaluated mood, quality of life, and well-being at weeks 0, 8, and 12. For each outcome measure, a repeated-measures analysis of variance model, which incorporated week 0 measurements as a covariate, was used to compare treatment groups at 8 and 12 weeks. Results There were statistically significant improvements in outcome in the experimental group compared with control group at both 8 and 12 weeks (except as indicated) for POMS total mood disturbance (and its subscales of anxiety, depression [8 weeks only], anger [12 weeks only], vigor, fatigue, and confusion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of physical, social [8 weeks only], emotional, and functional well-being), and WHO-5. Conclusion MSBR improved mood, breast- and endocrine-related quality of life, and well-being more effectively than standard care in women with stage 0 to III breast cancer, and these results persisted at three months. To our knowledge, this study provided novel evidence that MBSR can help alleviate long-term emotional and physical adverse effects of medical treatments, including endocrine treatments. MBSR is recommended to support survivors of breast cancer.

1 March 1992 in The Journal of Pediatrics
Verified
Journal Article
Closed access
BBB. Balkaran
B. Balkaran
GCG. Char
G. Char
JMJ.S. Morris
J.S. Morris
PTP.W. Thomas
P.W. Thomas
BSB.E. Serjeant
B.E. Serjeant
GSG.R. Serjeant
G.R. Serjeant